Dr. Bradley J. Monk, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
FL license ME166240
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 30 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 32 companies reported 246 payments worth $306,026 in total to this clinician.
| GlaxoSmithKline, LLC. | $77,418 |
|---|---|
| Merck Sharp & Dohme LLC | $64,654 |
| Takeda Pharmaceuticals U.S.A., Inc. | $46,802 |
| AbbVie Inc. | $20,782 |
| Genmab U.S., Inc. | $16,017 |
| AstraZeneca Pharmaceuticals LP | $11,428 |
| AstraZeneca UK Limited | $10,701 |
| Pharmaand GmbH | $9,425 |
| Compensation for services other than consulting (speaking, faculty) | $120,058 |
|---|---|
| Consulting Fee | $97,309 |
| Travel and Lodging | $83,459 |
| Food and Beverage | $5,200 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Travel and Lodging travel to WEST PALM BEACH, FL · in-kind | $19,566 |
| Merck Sharp & Dohme LLC Oct 28, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $17,856 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $16,486 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $14,080 |
| Merck Sharp & Dohme LLC Sep 15, 2025 | Travel and Lodging ONCOLOGY · travel to Milan, Italy · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $13,959 |
| GlaxoSmithKline, LLC. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $13,200 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,760 |
| GlaxoSmithKline, LLC. Jan 17, 2025 | Consulting Fee | $7,140 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Consulting Fee ZEJULA · ONCOLOGY | $7,140 |
| GlaxoSmithKline, LLC. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $6,400 |
All 120 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 19, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Pittsburgh, PA | $68.80 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $2,880 |
| Genmab U.S., Inc. Dec 7, 2025 | Travel and Lodging travel to Miami, FL | $196 |
| Genmab U.S., Inc. Dec 7, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $163 |
| Genmab U.S., Inc. Dec 6, 2025 | Consulting Fee | $4,000 |
| Genmab U.S., Inc. Dec 5, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $6,177 |
| Genmab U.S., Inc. Dec 5, 2025 | Consulting Fee | $3,800 |
| Genmab U.S., Inc. Dec 4, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $884 |
| Genmab U.S., Inc. Dec 4, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $60.02 |
| Genmab U.S., Inc. Dec 4, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $56.05 |
| GlaxoSmithKline, LLC. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| Genmab U.S., Inc. Dec 3, 2025 | Travel and Lodging travel to Miami, FL | $39.00 |
| Genmab U.S., Inc. Dec 3, 2025 | Travel and Lodging travel to Miami, FL | $12.00 |
| GlaxoSmithKline, LLC. Nov 18, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to York, PA | $72.20 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $915 |
| GlaxoSmithKline, LLC. Nov 13, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Pittsburgh, PA · in-kind | $616 |
| GlaxoSmithKline, LLC. Nov 13, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Pittsburgh, PA · in-kind | $335 |
| GlaxoSmithKline, LLC. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| Corcept Therapeutics Nov 10, 2025 | Consulting Fee | $1,200 |
| BioNTech SE Nov 5, 2025 | Consulting Fee | $4,400 |
| AstraZeneca UK Limited Nov 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,230 |
| BioNTech SE Nov 4, 2025 | Travel and Lodging travel to Cape Town, South Africa · in-kind | $124 |
| Merck Sharp & Dohme LLC Oct 31, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $408 |
| AstraZeneca Pharmaceuticals LP Oct 30, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
| Merck Sharp & Dohme LLC Oct 30, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $408 |
| Merck Sharp & Dohme LLC Oct 30, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $63.10 |
| Merck Sharp & Dohme LLC Oct 30, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $58.96 |
| GlaxoSmithKline, LLC. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $5,700 |
| Merck Sharp & Dohme LLC Oct 29, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $408 |
| Merck Sharp & Dohme LLC Oct 28, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $17,856 |
| Merck Sharp & Dohme LLC Oct 28, 2025 | Travel and Lodging ONCOLOGY · travel to Singapore, Singapore · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $408 |
| GlaxoSmithKline, LLC. Oct 28, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Fort Worth, TX | $94.25 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $14,080 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Travel and Lodging travel to MErida, Mexico Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| AstraZeneca UK Limited Oct 24, 2025 | Consulting Fee | $1,640 |
| GlaxoSmithKline, LLC. Oct 23, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to York, PA · in-kind | $1,313 |
| GlaxoSmithKline, LLC. Oct 23, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to York, PA · in-kind | $379 |
| Corcept Therapeutics Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,600 |
| AstraZeneca UK Limited Oct 9, 2025 | Consulting Fee | $3,280 |
| GlaxoSmithKline, LLC. Oct 9, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Fort Worth, TX · in-kind | $1,548 |
| GlaxoSmithKline, LLC. Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) ZEJULA · ONCOLOGY | $950 |
| Merck Sharp & Dohme LLC Oct 5, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Merida, Mexico · in-kind | $642 |
| Merck Sharp & Dohme LLC Oct 4, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Merida, Mexico · in-kind | $143 |
| Merck Sharp & Dohme LLC Oct 4, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Merida, Mexico · in-kind | $81.43 |
| Merck Sharp & Dohme LLC Oct 3, 2025 | Travel and Lodging travel to MErida, Mexico · in-kind | $1,004 |
| Merck Sharp & Dohme LLC Oct 3, 2025 | Travel and Lodging travel to MErida, Mexico · in-kind | $834 |
| Merck Sharp & Dohme LLC Oct 3, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Merida, Mexico · in-kind | $745 |
| Merck Sharp & Dohme LLC Oct 3, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Merida, Mexico · in-kind | $143 |
| Merck Sharp & Dohme LLC Oct 3, 2025 | Travel and Lodging travel to MErida, Mexico · in-kind | $134 |
| Merck Sharp & Dohme LLC Oct 3, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Merida, Mexico · in-kind | $81.06 |
| Merck Sharp & Dohme LLC Sep 16, 2025 | Travel and Lodging ONCOLOGY · travel to Milan, Italy · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $370 |
| Merck Sharp & Dohme LLC Sep 16, 2025 | Travel and Lodging ONCOLOGY · travel to Milan, Italy · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $3.48 |
| Merck Sharp & Dohme LLC Sep 15, 2025 | Travel and Lodging ONCOLOGY · travel to Milan, Italy · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $13,959 |
| Merck Sharp & Dohme LLC Sep 15, 2025 | Travel and Lodging ONCOLOGY · travel to Milan, Italy · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $370 |
| Merck Sharp & Dohme LLC Sep 15, 2025 | Travel and Lodging ONCOLOGY · travel to Milan, Italy · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $3.48 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Travel and Lodging travel to WEST PALM BEACH, FL · in-kind | $19,566 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,760 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,740 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Travel and Lodging travel to WEST PALM BEACH, FL · in-kind | $1,250 |
| AstraZeneca Pharmaceuticals LP Aug 13, 2025 | Travel and Lodging travel to Fort Lauderdale, FL | $181 |
| AstraZeneca Pharmaceuticals LP Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,920 |
| AstraZeneca UK Limited Aug 11, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,510 |
| Regeneron Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $4,812 |
| Regeneron Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $802 |
| Regeneron Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $802 |
| Regeneron Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $401 |
| Regeneron Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $401 |
| Ipsen Innovation Aug 4, 2025 | Consulting Fee | $1,268 |
| AbbVie Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $3,875 |
| Merck Sharp & Dohme LLC Jul 22, 2025 | Travel and Lodging ONCOLOGY · travel to Washington, DC · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $252 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $915 |
| AbbVie Inc. Jul 15, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to PEMBROKE PINES, FL · in-kind | $182 |
| Merck Sharp & Dohme LLC Jul 9, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $4,480 |
| GlaxoSmithKline, LLC. Jun 27, 2025 | Consulting Fee | $2,000 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $16,486 |
| AstraZeneca Pharmaceuticals LP Jun 20, 2025 | Consulting Fee | $1,370 |
| GlaxoSmithKline, LLC. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $13,200 |
| GlaxoSmithKline, LLC. Jun 18, 2025 | Consulting Fee | $288 |
| GlaxoSmithKline, LLC. Jun 18, 2025 | Travel and Lodging travel to RIO, Brazil | $195 |
| Pfizer Inc. Jun 12, 2025 | Consulting Fee TIVDAK · ONCOLOGY | $720 |
| Merck Sharp & Dohme LLC Jun 9, 2025 | Consulting Fee ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $960 |
| AstraZeneca Pharmaceuticals LP Jun 5, 2025 | Consulting Fee | $685 |
| GlaxoSmithKline, LLC. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) ZEJULA · ONCOLOGY | $4,800 |
| Corcept Therapeutics May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,000 |
| GlaxoSmithKline, LLC. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ZEJULA · ONCOLOGY | $4,800 |
| GlaxoSmithKline, LLC. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) JEMPERLI · ONCOLOGY | $6,400 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $3,875 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $3,488 |
| Pharmaand GmbH Apr 30, 2025 | Consulting Fee Rubraca · PARP inhibitor | $3,575 |
| Janssen Global Services, LLC Apr 30, 2025 | Consulting Fee | $2,420 |
| GlaxoSmithKline, LLC. Apr 28, 2025 | Travel and Lodging ZEJULA · ONCOLOGY · travel to Houston, TX · in-kind | $675 |
| GlaxoSmithKline, LLC. Apr 28, 2025 | Travel and Lodging ZEJULA · ONCOLOGY · travel to Houston, TX · in-kind | $321 |
| GlaxoSmithKline, LLC. Apr 23, 2025 | Travel and Lodging ZEJULA · ONCOLOGY · travel to Kentwood, MI · in-kind | $1,700 |
| GlaxoSmithKline, LLC. Apr 23, 2025 | Travel and Lodging ZEJULA · ONCOLOGY · travel to Kentwood, MI · in-kind | $218 |
| AbbVie Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) ELAHERE · ONCOLOGY | $5,425 |
| Illumina, Inc. Apr 14, 2025 | Consulting Fee Oncology Testing · Genetics | $1,280 |
| GlaxoSmithKline, LLC. Apr 12, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Portland, OR · in-kind | $1,049 |
| GlaxoSmithKline, LLC. Apr 12, 2025 | Travel and Lodging JEMPERLI · ONCOLOGY · travel to Portland, OR · in-kind | $279 |
| AbbVie Inc. Apr 11, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind | $443 |
| AbbVie Inc. Apr 11, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind | $304 |
| AbbVie Inc. Apr 10, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to DALLAS, TX · in-kind | $30.34 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Consulting Fee ZEJULA · ONCOLOGY | $7,140 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Consulting Fee LYNPARZA · ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $610 |
| Histosonics, Inc. Mar 27, 2025 | Consulting Fee | $3,325 |
| AbbVie Inc. Mar 27, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to TAMPA, FL · in-kind | $2,115 |
| AbbVie Inc. Mar 27, 2025 | Travel and Lodging ELAHERE · ONCOLOGY · travel to TAMPA, FL · in-kind | $280 |
| Array Biopharma Inc Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) LORBRENA; BRAFTOVI; MEKTOVI · ONCOLOGY | $78.95 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee | $1,860 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee | $930 |
| Incyte Corporation Mar 11, 2025 | Consulting Fee | $3,105 |
| Incyte Corporation Mar 11, 2025 | Consulting Fee | $3,105 |
| Pharmaand GmbH Mar 1, 2025 | Consulting Fee Rubraca · PARP inhibitor | $5,850 |
| Daiichi Sankyo Inc. Feb 26, 2025 | Consulting Fee | $3,720 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Consulting Fee | $1,370 |
| Daiichi Sankyo Inc. Feb 20, 2025 | Consulting Fee | $1,860 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Consulting Fee | $1,370 |
| GlaxoSmithKline, LLC. Feb 7, 2025 | Travel and Lodging travel to RIO DE JANEIRO, Brazil · in-kind | $4,009 |
| Eli Lilly and Company Jan 27, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| GlaxoSmithKline, LLC. Jan 17, 2025 | Consulting Fee | $7,140 |
| BioNTech SE Jan 16, 2025 | Consulting Fee | $2,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $439,424 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Beone Medicines Ltd. · Terminated · NCT05381909 - RAMP 201 - GOG-3052
Verastem, Inc. - Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Genmab U.S., Inc. - An Open Label, Randomized, Multicenter, controlled, Phase III Study of First-line Trastuzumab Deruxtecan (T-DXd) monotherapy versus SoC in patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.